Pacific Biomarkers Launches New Website

Pacific Biomarkers Launches New Website
PacBio.com Offers Fresh, User-Friendly Interface for Customers and Investors

SEATTLE, WA, Jul 28, 2010 (MARKETWIRE via COMTEX) -- Pacific Biomarkers, Inc. , a provider of biomarker laboratory services to the pharmaceutical, biotechnology and diagnostics industries, unveiled its new website on Friday, July 23. The site, www.PacBio.com, incorporates numerous features to make browsing a more fruitful experience for the Company's current and potential customers and investors.

The new site includes a "Biomarker Menu Search" that allows users to identify a specific PacBio biomarker either alphabetically or by therapeutic area (e.g. cardiovascular disease, musculoskeletal, diabetes and endocrine, nutrition and nutrition outcomes, inflammation, acute organ injury and immunogenicity). In addition to standard corporate information, visitors will find information on PacBio's laboratory services (e.g. clinical trial support, diagnostic development and lab certifications); information for investors; and access to PacBio's white papers, educational brochures, newsletters and posters. Especially notable developments are prominently displayed on the homepage. Finally, visitors can access PacBio webcasts through the site.

Ron Helm, Chief Executive Officer and Chairman of Pacific Biomarkers, said, "A significant part of PacBio's mission is presenting those interested in the Company with the information they want in the quickest and most organized way. We believe our new website advances this goal by presenting our range of services and activities in an attractive and easy-to-access format. As our official online portal, it accurately reflects the variety and excitement of what we have to offer to those with whom we do business."

About Pacific Biomarkers, Inc. Pacific Biomarkers, Inc. (PBI) has been supporting clinical trials since 1989. PBI is a biomarker services laboratory supporting pre-clinical work and FIH through Phase IV clinical trials. The Company provides expert services in the areas of cardiovascular and musculoskeletal diseases, diabetes, obesity, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, New York State, and the Lipid Standardization Program. PBI's clients include many of the world's largest pharmaceutical, biotech, and diagnostic companies. PBI also provides clinical biomarker services focusing on the emerging field of biomarker assay development and testing. Services include validating and performing custom assays for novel clinical biomarkers, immunogenicity testing, cell-based assays, mass spectrometry, and multiplex testing.

PBI is headquartered in Seattle, Washington, and its common stock trades on the OTC Bulletin Board under the symbol "PBMC."

For more information about PBI, visit the company's website at www.pacbio.com.

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.